EPISODE · Oct 28, 2022 · 13 MIN
Rare Disease Report: The FDA Decision for Pompe Disease Therapy
from HCPLive Podcasts · host HCPLive.com
The FDA is expected to announce the final decision for the dual therapy AT-GAA, which uses miglustat in combination with cipaglucosidase alfa for treating Pompe disease, an inherited and often times fatal disorder. Expert Barry Byrne discusses the characteristics of the condition and what this FDA decision will mean for treatment.
NOW PLAYING
Rare Disease Report: The FDA Decision for Pompe Disease Therapy
No transcript for this episode yet
Similar Episodes
Jun 15, 2022 ·8m
May 25, 2022 ·20m
May 19, 2022 ·16m
May 15, 2022 ·34m
May 12, 2022 ·1m